# Avacta and Medusa19 Enter into a Distribution Agreement for COVID-19 Antigen Test

- Link: https://www.directorstalkinterviews.com/avacta-and-medusa19-enter-into-a-distribution-agreement-for-covid-19-antigen-test/412823550
- Published: 2020-05-20T07:07:55+01:00
- Author: Giles Arbor

**Global, exclusive, direct-to-consumer sales and marketing agreement for COVID-
19 self-testing**

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of Affimer biotherapeutics and reagents, has this morning announced
that it has entered into an exclusive distribution agreement with Medusa19 Limited
for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.

Avacta recently announced a partnership with Cytiva (formerly GE Healthcare Life
Sciences) to develop a saliva-based rapid antigen test to indicate whether a person
has the COVID-19 infection which will be in the form of a simple test strip. The
test is intended to give a result within minutes and for use by both healthcare 
professionals and consumers.

[DirectorsTalk caught up with CEO Alastair Smith to discuss today’s news and the potential treatment for COVID-19 which you can listen to here.](https://www.directorstalkinterviews.com/avacta-group-antigen-distribution-agreement-and-potential-treatment-for-covid-19-interview/412823611)

The Group has agreed an exclusive distribution agreement with Medusa19 for the supply
of the COVID-19 rapid test direct to consumers globally, subject to the necessary
regulatory approvals. Medusa19 has been established by Richard Hughes and Mahmud
Kamani, both founder shareholders of [Boohoo](https://www.directorstalkinterviews.com/company/boohoo/boo.l).
com and shareholders of Avacta^(1), to build a global consumer self-testing business.
Medusa19’s initial focus will be on COVID-19 home testing and it is currently investing
in global e-commerce, logistics and customer support infrastructure in preparation
for Avacta’s COVID-19 test launch. Medusa19 will also have non-exclusive rights 
to supply the tests to businesses for workforce testing. The distribution agreement
includes a profit-sharing arrangement.  

The global demand for rapid antigen tests, which will be critical to lockdown exit
strategies around the world in order to get healthy, non-contagious people back 
to work, could be many millions of tests per month. There will also be an ongoing
need for several years for this type of testing as the disease recurs.

Avacta recently announced that it rapidly developed Affimer reagents that detect
the SARS-COV-2 virus spike protein and it has now supplied those to Cytiva for test
development. The Group is intending to establish further rapid test strip manufacturing
partners in anticipation of a very high demand for the COVID-19 antigen test.

> **Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: **
> “I am delighted to have entered into this distribution agreement with Medusa19,
> which will provide a global route direct-to-consumer for Avacta’s rapid point-
> of-care COVID-19 antigen test. The potential size of this market, and the expected
> demand from businesses for workforce screening, is substantial.
> The significant investment that Medusa19 is making in conjunction with the track
> records of the Medusa19 team, gives me great confidence in the rapid growth of
> direct-to-consumer sales of the Avacta COVID-19 test across the United Kingdom,
> European Union and the United States subject to the necessary regulatory approvals.
> I expect the commercial impact of this partnership to be very significant to Avacta.
> I am looking forward to working with the Medusa19 team on commercialising the 
> COVID-19 rapid test and other consumer diagnostic tests that Avacta develops in
> the future, in line with the Group’s Affimer diagnostics strategy.”

> **Richard Hughes and Mahmud Kamani, Founders of Medusa19 commented:**
> “We immediately recognised the global opportunity to distribute the simple and
> unique saliva-based COVID-19 rapid test being developed by Avacta based on their
> unique and powerful Affimer platform.
> Medusa19 will enable end-to-end supply of these tests on a global basis subject
> to regulatory approval and manufacturing capacity which will be key. The enormous,
> world-wide demand for these tests requires a robust and scalable platform which
> we are in the process of creating. Hundreds of millions of tests are required 
> and this demand will continue.
> The test being created by Avacta and its partners is intended to enable an individual
> with the COVID-19 infection, whether they have symptoms or not, to be identified
> before antibodies have been generated by the body. Given this test will be saliva
> based, it could be used in airports, offices, factories and in the home environment,
> providing a result within minutes and with no requirement for medical supervision.
> It is potentially ground-breaking and a major step forward in the fight against
> COVID-19.
> We look forward to working with Alastair and his team and to distributing other
> Avacta products as they become available in due course.”

^(1) Clare Hughes (wife of Richard Hughes) and Umar Mahmud Kamani (son of Mahmud
Kamani).

Share on:
